Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study

Table 7 Proteinuria during DSG treatment: proteinuria (g/day) in the study population (n = patient number)

	Patient number (n)	Proteinuria (study population)	P-value compared to entry
Entry	20	5.124 +/- 4,379
cycle 4	20	2.604 +/- 2,580	0.0045
cycle 6	14	2.603 +/- 2,521	0.0392
cycle 9	12	3.374 +/- 4,787	0.028

ISSN: 1478-6362